Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R.

Blood. 2005 May 15;105(10):4106-14. Epub 2005 Feb 3.

2.

[Factors affecting posttransfusion platelet efficiency "close relationship between patient and product"].

Sensebé L.

Transfus Clin Biol. 2007 May;14(1):90-3. Epub 2007 May 21. French.

PMID:
17513157
4.

The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.

Benson K, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, Elfenbein G.

Semin Oncol. 1993 Oct;20(5 Suppl 6):102-9. Review.

PMID:
8211211
6.

Platelet transfusion: a dose-response study.

Norol F, Bierling P, Roudot-Thoraval F, Le Coeur FF, Rieux C, Lavaux A, Kuentz M, Duedari N.

Blood. 1998 Aug 15;92(4):1448-53.

7.

Clinical factors influencing the efficacy of pooled platelet transfusions.

Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA, et al.

Blood. 1988 Feb;71(2):383-7.

8.

A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.

Messerschmidt GL, Makuch R, Appelbaum F, Ungerleider RS, Abrams R, O'Donnell J, Holohan TV, Fontana J, Wright D, Anagnou NP, et al.

Cancer. 1988 Aug 15;62(4):795-801.

9.

The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.

Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, Granger S, Slichter SJ.

Blood. 2012 Jun 7;119(23):5553-62. doi: 10.1182/blood-2011-11-393165. Epub 2012 Apr 10.

10.

Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates.

Peter-Salonen K, Bucher U, Nydegger UE.

Blut. 1987 Apr;54(4):207-12.

PMID:
3828538
11.

Prevention and management of platelet transfusion refractoriness.

Novotny VM.

Vox Sang. 1999;76(1):1-13. Review.

PMID:
9933848
12.
13.

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B.

Lancet. 2002 Jun 22;359(9324):2145-52.

PMID:
12090979
14.
15.
16.

Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.

Slichter SJ, Bolgiano D, Kao KJ, Kickler TS, McFarland J, McCullough J, Woodson R.

Transfus Med Rev. 2011 Apr;25(2):102-10. doi: 10.1016/j.tmrv.2010.11.002. Epub 2011 Feb 23.

17.

Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.

Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG.

Transfusion. 1995 Aug;35(8):645-52.

PMID:
7631404
18.

Factors influencing 20-hour increments after platelet transfusion.

Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J.

Transfusion. 1991 Jun;31(5):392-6.

PMID:
2048176
19.

Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith KJ, Raife T, Tomita D, Armstrong S.

Blood. 2001 Sep 1;98(5):1346-51.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk